The promise of lung master protocol for squamous cell carcinoma: one trial to rule them all, one trial to find them…?
The recently initiated lung master protocol (Lung-MAP) trial provides hope that the successes of targeted molecular therapy in lung adenocarcinoma can be extended to squamous cell carcinoma (SCC). It also is a template for rapid translation of clinical research through regulatory approval to clinical practice. This is vital in cancers with multiple possible oncogenic genomic aberrations, for which clinical trials would be too costly and impractical to conduct for individual targets making up less than 10% of cases.
1 Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia ; 2 Department of Cardiothoracic Surgery, St Vincent's Hospital, Melbourne, Victoria, Australia ; 3 Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia ; 4 Department of Anatomical Pathology, St Vincent's Hospital, Melbourne, Victoria, Australia.
Gavin Michael
GM
Wright
1 Department of Surgery, University of Melbourne, Melbourne, Victoria, Australia ; 2 Department of Cardiothoracic Surgery, St Vincent's Hospital, Melbourne, Victoria, Australia ; 3 Department of Pathology, University of Melbourne, Melbourne, Victoria, Australia ; 4 Department of Anatomical Pathology, St Vincent's Hospital, Melbourne, Victoria, Australia.
Prudence Anne
PA
Russell
Biomarker; clinical trial; non-small cell lung cancer (NSCLC)